摘要
随着近年来治疗手段的发展,目前早期乳腺癌患者的5年生存率可达90%。然而,晚期乳腺癌几乎不可治愈。有效的化疗、内分泌治疗及靶向治疗等虽已改善了晚期乳腺癌患者的生存和预后,耐药及肿瘤进展仍不可避免。血管生成是肿瘤生长和侵袭、转移不可或缺的步骤之一,通过阻断肿瘤周围新生血管生成从而抑制肿瘤生长的抗血管生成药物已成为恶性肿瘤治疗中的关键一环。目前,可应用于晚期乳腺癌的抗血管生成药物均未在一线治疗中展现显著临床获益。本文就阿帕替尼单药或联合其他抗肿瘤药物在晚期乳腺癌治疗中的临床疗效和安全性,及相关生物标志物研究进展展开综述。阿帕替尼单药用于多线治疗失败后的晚期转移性乳腺癌可取得明显临床疗效且不良反应可控,阿帕替尼联合化疗及免疫治疗方案在晚期难治性乳腺癌患者中取得良好疗效。
With the development of treatment strategies in recent years, the 5-year survival rate of early breast cancer patients is up to 90%. However, advanced breast cancer is almost incurable. Although effective chemotherapy, endocrine therapy and targeted therapy have improved the survival and prognosis of patients with advanced breast cancer, drug resistance and tumor progression are still inevitable. Angiogenesis is indispensable for tumor growth, invasion and metastasis. Anti-angiogenic drugs, which block neovascularization around tumors to inhibit tumor growth, have become key treatment of malignancy. Currently, none of the anti-angiogenic drugs applied in advanced breast cancer patients have shown significant clinical benefit for first-line treatment. In this paper, we reviewed the clinical efficacy and safety of apatinib alone or in combination with other anti-tumor agents in advanced breast cancer treatment, and summarized the results of researches on related biomarkers. Apatinib monotherapy for advanced metastatic breast cancer after the failure of multi-line therapy can achieve significant clinical efficacy with well-tolerated toxicity. The combination of apatinib with chemotherapy and immunotherapy also brings good outcome in refractory advanced patients.
作者
刘佳璇
何迈越
李俏
徐兵河
Liu Jiaxuan;He Maiyue;Li Qiao;Xu Binghe(Department of Internal Medicine,National Cancer Center/National Clinical Research Center for Oncology/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College)
出处
《中华乳腺病杂志（电子版）》
CAS
CSCD
2023年第1期1-5,共5页
Chinese Journal of Breast Disease(Electronic Edition)
